Epstein-barr viruses (EBVs) deficient in EBV-encoded RNAs have higher levels of latent membrane protein 2 RNA expression in lymphoblastoid cell lines and efficiently establish persistent infections in humanized mice

Gregorovic, Goran; Boulden, Elizabeth A; Bosshard, Rachel; Elgueta Karstegl, Claudio; Skalsky, Rebecca; Cullen, Bryan R; Gujer, Cornelia; Råmer, Patrick; Münz, Christian; Farrell, Paul J

Abstract: Functions of Epstein-Barr virus (EBV)-encoded RNAs (EBERs) were tested in lymphoblastoid cell lines containing EBER mutants of EBV. Binding of EBER1 to ribosomal protein L22 (RPL22) was confirmed. Deletion of EBER1 or EBER2 correlated with increased levels of cytoplasmic EBV LMP2 RNA and with small effects on specific cellular microRNA (miRNA) levels, but protein levels of LMP1 and LMP2A were not affected. Wild-type EBV and EBER deletion EBV had approximately equal abilities to infect immunodeficient mice reconstituted with a human hematopoietic system.

DOI: https://doi.org/10.1128/JVI.01873-15

Originally published at: Gregorovic, Goran; Boulden, Elizabeth A; Bosshard, Rachel; Elgueta Karstegl, Claudio; Skalsky, Rebecca; Cullen, Bryan R; Gujer, Cornelia; Råmer, Patrick; Münz, Christian; Farrell, Paul J (2015). Epstein-barr viruses (EBVs) deficient in EBV-encoded RNAs have higher levels of latent membrane protein 2 RNA expression in lymphoblastoid cell lines and efficiently establish persistent infections in humanized mice. Journal of Virology, 89(22):11711-11714. DOI: https://doi.org/10.1128/JVI.01873-15
Epstein-Barr virus (EBV)-encoded RNAs (EBERs) are abundant viral noncoding RNAs in EBV-transformed lymphoblastoid cell lines (LCLs). We previously identified cell genes whose expression in EBV LCLs correlates with deletion of EBER1 or EBER2 (1); here, we used LCLs to test various mechanisms that have been proposed for EBER function.

Functions of Epstein-Barr virus (EBV)-encoded RNAs (EBERs) were tested in lymphoblastoid cell lines containing EBER mutants of EBV. Binding of EBER1 to ribosomal protein L22 (RPL22) was confirmed. Deletion of EBER1 or EBER2 correlated with increased levels of cytoplasmic EBV LMP2 RNA and with small effects on specific cellular microRNA (miRNA) levels, but protein levels of LMP1 and LMP2A were not affected. Wild-type EBV and EBER deletion EBV had approximately equal abilities to infect immunodeficient mice reconstituted with a human hematopoietic system.

Binding of EBER1 to ribosomal protein L22 (RPL22) in LCLs is confirmed, but no effect of EBER1 on p53 protein level was detected. EBER1 can bind to RPL22 (2), and studies on RPL22 knockout mice (3, 4) showed a p53-dependent defect in pro-B cells (4). The effect is thought to involve RPL22 binding to p53 mRNA, reducing translation of p53 (5). It is possible that EBER1 could modulate this pathway, although EBV infects mature B cells, in which the RPL22 phenotype was previously reported to be absent (4). We confirmed binding of RPL22 to endogenous EBER1 in extracts of an LCL (Fig. 1A). The p53 protein level was determined by Western blotting in LCLs, and the response to treatment using cisplatin, which stabilizes p53, was also tested. There was no significant difference in the p53 levels or responses between the cells with and without EBER1 expression (Fig. 1B), so EBER1 does not appear to affect p53 expression in LCLs.

Effect of EBERs on cellular miRNAs. To determine whether the EBERs might affect cellular microRNAs (miRNAs), we used LCLs containing wild-type (wt) B95-8 bacterial artificial chromo-

FIG 1 (A) Flag-tagged RPL22 (L22) or negative-control (C) (Flag-tagged Schlafen) proteins were expressed by Neon transfection in LCL cells containing B95-8 BAC EBV. Cell extracts were incubated with M2 anti-FLAG antibody (Sigma-Aldrich) bound to protein G Sepharose beads. RNA was extracted from the beads (using immunoprecipitation [IP]) and the unbound supernatant (Sup) and tested for EBER by Northern blotting. (B) Cells from three independent ΔEBER1 LCLs (light gray bars) or wt EBV LCLs (WT; black bars) were treated with 20 μg/ml cisplatin (C) in triplicate or were left untreated (U) as a control. For each sample, 2 ml of cell suspension (at 2.5 × 10^6 viable cells/ml, determined by trypan blue exclusion) was set up per well in 6-well plates with or without cisplatin as indicated. The number of viable cells (excluding trypan blue) was determined after 16 h, and p53 protein was detected by Western blotting of cell extracts made at the same time point. DOI antibody (Santa Cruz) was used for detection of p53 by Western blotting. Actin was used as a loading control on the Western blots.
some (BAC) EBV, EBER1 or EBER2 deletion mutants, or revertant viruses. Total RNA was isolated from each LCL, and small RNAs were used to generate Illumina sequencing libraries (6). Appropriate expression of the EBER1 and EBER2 RNAs was confirmed by Northern blotting (Fig. 2A).

Sequencing detected miRNAs from all 8 EBV B95-8 pre-miRNAs and 491 mature human cellular miRNAs. Sequence reads are available at NCBI BioProject PRJNA287267. The general pattern of viral and cellular miRNA expression was comparable to that observed previously in EBV B95-8 LCLs (6). miR-190a-3p, miR-190a-5p, and miR-33a-3p were upregulated in the EBER1-deleted LCLs compared to wild-type (wt) and EBER1 revertant (E1R) LCLs. “A” and “B” denote the two individual LCLs analyzed for each condition. About 10 million sequencing reads were obtained for each LCL library. Reads were processed as described previously (6) using scripts from the fastx toolkit (http://hannonlab.cshl.edu/fastx_toolkit/). To determine miRNA levels, reads were aligned to the human (HG19) and EBV B95-8 genomes and annotated according to mirbase v21 (http://www.mirbase.org/).

To determine miRNA expression levels, miRNA read counts were obtained using the quantifier module of miRDeep2 (14) (see Table S1 in the supplemental material). To identify differentially expressed (DE) miRNAs, miRNA read counts were analyzed by edgeR using trimmed mean of M (TMM) values for normalization (15, 16). For inclusion in the analysis, a minimum of 40 reads per miRNA in at least one of the 10 LCL libraries was required. DE miRNAs with a LogFC P value of <0.05 are reported in Table S2. Normalized miRNA read counts for miR-33a in EBER1-deleted LCLs (Fig. 2C). Normalized miRNA read counts for miR-340 and miR-190 in EBER2-deleted LCLs. Summary of log fold changes (logFC) of selected cellular miRNAs showing significant changes correlating with EBER1 or EBER2 expression as determined by deep sequencing and edgeR analysis. Relative levels of miR-340-5p and miR-340-3p determined by TaqMan qRT-PCR assays in LCLs. The expression levels of miRNAs were normalized to RNU48. The values represent means ± standard errors (SE) of the results of analysis of 6 independent samples per EBV type (5 in the case of EBER1 revertants). The wild-type expression levels were set to 1 for each miRNA, whereas the levels of other samples were expressed relative to the wild-type level. Each cDNA sample was analyzed in triplicate.

The results of additional TaqMan quantitative reverse transcription-PCR (qRT-PCR) assays performed on RNA from independently established LCLs supported the idea of expression of primary miRNA transcripts were affected (Fig. 2B), consistent with a recent report on miR-190 (9).
Cytoplasmic RNA from two LCLs each for EBV wild type (WT), deletion of EBER1 (ΔE1), revertant (E1R), and deletion of EBER2 (ΔE2) or revertant (E2R) was used for cDNA synthesis performed with either random primers (A) or oligo(dT) (B) using a ProtoScript First Strand cDNA synthesis kit (New England BioLabs). Quantitative PCR (Q-PCR) performed with the same primers as those described in reference 10 was then used in duplicate assays to measure the levels of RNA for LMP1, LMP2A, and LMP2B, using GAPDH (glyceraldehyde-3-phosphate dehydrogenase) as a reference. The threshold cycle ($\Delta \Delta CT$) method of comparative PCR (17) was used to analyze the results, expressed as fold change relative to the E1R LMP1 value. (C) Radioimmunoprecipitation assay (RIPA) lysates were prepared from LCLs, and equal amounts of cell protein were analyzed by Western immunoblotting. Membranes were probed with a 1/1,000 dilution of anti-LMP2A (Abcam; 14B7), a 1/500 dilution of anti-LMP1 (Dako; clone CS.1-4), or a 1/5,000 dilution of anti-β actin (Sigma; AC-74). Secondary antibodies were horseradish peroxidase-conjugated sheep anti-mouse immunoglobulin (GE Healthcare) or horseradish peroxidase-conjugated rabbit anti-rat immunoglobulin (Sigma). Bound immunocomplexes were detected by enhanced chemiluminescence (GE Healthcare).

Newborn HLA-A*0201 transgenic NOD/LtSz-Scid IL2Rnull (NSG-A2tg) mice were irradiated and injected intrahepatically with CD34+ human hematopoietic progenitor cells as described previously (18). The reconstitution of human immune system components in the peripheral blood was analyzed prior to the beginning of experiments (normally 12 weeks after engraftment). Groups of mice were infected with 10^5 infectious units of virus and monitored over a 4- to 8-week period in three experiments, each using different groups of reconstituted mice. EBV loads in spleen and whole blood were quantified 4 weeks after infection for wild-type (EBV wt), EBER1-deficient (ΔE1), EBER2-deficient (ΔE2), EBER1- and EBER2-deficient (ΔE12), and EBER2 revertant (E2rev) viruses. (B) CD8+ T cell expansion was slightly elevated in the absence of EBER1. The T cell ratio of CD8+ to CD4+ was assessed by flow cytometry after 4 weeks of infection with the same viruses as described for panel A. The composition of blood and spleen samples from the humanized mice was analyzed using anti-human CD45 (HI30; Biolegend), anti-CD3 (UCHT1; Biolegend), anti-CD4 (RPA T4; Biolegend), anti-CD8 (SK1; Biolegend), anti-HLA-DR (L243; Biolegend), anti-CD45RO (UCHL1; BD Pharmingen), and anti-CD19 (HIB19; BD Pharmingen). Spleens were mechanically disrupted and filtered through a 70-μm-pore-size cell strainer. Erythrocytes were lysed in whole blood or in spleen suspensions using NH4Cl. Cell suspensions were stained with the indicated antibodies for 15 min at 4°C and washed. Statistical analysis for all mouse experiments used two-tailed t tests. A P value of <0.05 was considered statistically significant.
Deletion of EBER1 or EBER2 correlates with raised levels of LMP2 RNAs in LCLs. EBER2 was recently shown to bind PAx5 and to promote PAx5 binding to the terminal repeat region of the EBV genome (10). Knockdown of EBER2 by small interfering (siRNA) caused a 50% increase in LMP1 and LMP2 RNA levels (10). Using quantitative PCR (qPCR) with the same primers on cytoplasmic RNA, we did not observe any significant difference between the EBER2 deletion LCLs and wild-type EBV LCLs in the levels of LMP1 RNA, but LMP2A and LMP2B RNA levels were 2-fold to 3-fold higher when either EBER1 or EBER2 was deleted (Fig. 3A and B), particularly when the cDNA synthesis was primed with oligo(dT) (Fig. 3B). LMP1 and LMP2A protein levels are quite variable in LCLs (Fig. 3C), and there was no apparent correlation with EBER expression. Our results thus provide some support for the idea of EBER2 tending to reduce the level of LMP2 RNA (10), but the specific binding of EBER2 to PAx5 and association with the terminal repeat may not mediate the LMP2 RNA effect that we observed, since there was an increase in the level of LMP2 RNA when either EBER1 or EBER2 was deleted. The focus of the previous study on EBER2 meant that an effect of EBER1 deletion on LMP2 RNA levels was not tested in those experiments (10).

Infection of mice with a human hematopoietic system with EBV lacking EBER genes. Using the EBV mutant EBV strains, we tested whether EBERs affect establishment of EBV infection in NSG mice with a humanized hematopoietic system (11). In three separate experiments involving a total of 44 correctly reconstituted mice, there was no significant difference between the frequencies of infection detected in the blood or in the spleen with deletion of either or both EBER genes from the virus genome. Spleen and blood viral loads are shown in Fig. 4A.

Analyzing parameters of cell-mediated immune responses toward the viral infections, we observed a tendency toward more-pronounced CD8+ T cell expansion in the infection with EBER1-deficient viruses (Fig. 4B). However, this tendency was primarily observed in one experiment and was not present in infections with an EBV deficient in both EBERs.

Most studies have focused on cell-intrinsic functions for EBERs, but EBERs have also been reported to be released from cells (12) and in exosomes (13), potentially affecting immune or inflammatory responses (M. Pegtel, personal communication). Most likely, physiological phenotypes for the EBERs will be revealed by in vivo infection challenged by normal immune responses. We have now shown that deletion of EBERs does not prevent infection of humanized mice, making this type of analysis possible.

ACKNOWLEDGMENTS

We thank David Wiest for helpful discussions.

This work was supported by grants to P.J.F. from Leukemia and Lymphoma Research (11012) and by NIH grant R01-AL067968 to B.R.C. R.S. was supported in part by NIH grant T32-CA90111. C.M. grant support was from Cancer Research Switzerland (KFS-3234-08-2013), Worldwide Cancer Research (14-1033), KSFP445 and KSFP445H11 of the University of Zurich, the Baugarten Foundation, the Sobek Foundation, Fondation Acercia, the Swiss Vaccine Research Institute, and the Swiss National Science Foundation (310030_149799 and CRSII1_136241).

REFERENCES

1. Gregorovic G, Bosshard R, Karstegel CE, White RE, Pattle S, Chiang AK, Dittrich-Breiholz O, Kracht M, Russ R, Farrell PJ. 2011. Cellular gene expression that correlates with EBER expression in Epstein-Barr virus-infected lymphoblastoid cell lines. J Virol 85:3535–3545. http://dx.doi.org/10.1128/JVI.02086-10.
2. Toczkowski DP, Materia AG, Ward DC, Steitz JA. 1994. The Epstein-Barr virus (EBV) small RNA EBER1 binds and relaxolizes ribosomal protein L22 in EBV-infected human B lymphocytes. Proc Natl Acad Sci USA 91:3463–3467. http://dx.doi.org/10.1073/pnas.91.8.3463.
3. Anderson SJ, Lauritsen JPH, Hartman MG, Foushee AMD, Lefebvre JM, Shinton SA, Gerhardt B, Hardy RR, Oravecz T, Wiest DL. 2007. Ablation of ribosomal protein L22 selectively impairs [alpha][beta] T cell development by activation of a p53-dependent checkpoint. Immunity 26: 759–772. http://dx.doi.org/10.1016/j.immuni.2007.04.012.
4. Lee N, Moss WN, Yario TA, Steitz JA. 1994. miRDeep2 accurately identifies known and hundreds of novel microRNA genes in lymphoblastoid cell lines. PLoS Pathog 8:e1002484. http://dx.doi.org/10.1371/journal.ppat.1002484.
5. Rashkovan M, Vadnais C, Ross J, Gigoux M, Suh WK, Gu W, Kosan C, Moroy T. 2014. Mir-1 regulates translation of Trp53 via ribosomal protein L22 in cells undergoing V(DJ) recombination. Proc Natl Acad Sci USA 111:E5411–E5419. http://dx.doi.org/10.1073/pnas.1412071111.
6. Bioloform N, Corcoran DL, Gottwald K, Frank CL, Hafer M, Nussbaum JD, Feederle R, Delecluse HJ, Luz, MG, Schmittgen TD, Livak KJ. 2010. A scaling normalization method for comparative C(T) method. Nat Protoc 5:1038–1043. http://dx.doi.org/10.1038/nprot.2008.73.
7. Skalsky RL, Kang D, Linnstaedt SD, Cullen BR. 2014. Evolutionary conservation of primate lymphocryptovirus microRNA targets. J Virol 88:1617–1635. http://dx.doi.org/10.1128/JVI.02071-13.
8. Kramer EM, Shao Y, Wang Y, Yuan Y. 2014. miR-190 is upregulated in Epstein-Barr virus-type I latency and modulates cellular microRNAs involved in cell survival and viral reactivation. Virology 464 – 465:184–195.
9. Lee N, Moss WN, Yario TA, Steitz JA. 2015. B2/R2 loss impairs the development of B lymphocytes by activating a p53-dependent checkpoint. J Immunol 194:200–209. http://dx.doi.org/10.4049/jimmunol.1402242.
10. Gregorovic et al. From: Journal of Virology. Volume 89, Number 22, November 2015
11. Chen SJ, Shah GD, Chen YH, Liu CY, Chang KP, Chang YS, Chen HC. 2010. Characterization of Epstein-Barr virus miRNAs in nasopharyngeal carcinoma by deep sequencing. PLoS One 5:e125745. http://dx.doi.org/10.1371/journal.pone.00125745.
12. Skalsky RL, Kang D, Linnstaedt SD, Cullen BR. 2014. Evolutionary conservation of primate lymphocryptovirus microRNA targets. J Virol 88:1617–1635. http://dx.doi.org/10.1128/JVI.02071-13.
13. Gujer C, Chatterjee B, Landtving V, Raykova A, McHugh D, Munz C. 2015. Animal models of Epstein-Barr virus infection. Curr Opin Virol 13:166–170. http://dx.doi.org/10.1016/j.coviro.2015.03.014.
14. Ikaw K, Zhao L, Samanta M, Matsumoto M, Ebihara T, Saya T, Imai S, Hiino M, Kawai T, Kato K. 2009. Epstein-Barr virus (EBV)-encoded small RNA is released from EBV-infected cells and activates signaling from Toll-like receptor 3. J Exp Med 206:2091–2099. http://dx.doi.org/10.1084/jem.20081761.
15. Ahmed W, Philip PS, Tariq S, Khan G. 2014. Epstein-Barr virus-encoded small RNAs (EBERs) are present in fractions related to exosomes released by EBV-transformed cells. PLoS One 9:e99163. http://dx.doi.org/10.1371/journal.pone.0099163.
16. Friedlander MR, Mackowiak SD, Li N, Chen W, Rajewsky N. 2012. miRDeep2 accurately identifies known and hundreds of novel microRNA genes in seven animal clades. Nucleic Acids Res 40:38–57. http://dx.doi.org/10.1093/nar/gkr688.
17. Robinson MD, McCarthy DJ, Smyth GK. 2010. edgeR: A Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26:139–140. http://dx.doi.org/10.1093/bioinformatics/btp616.
18. Robinson MD, Oshlack A. 2010. A scaling normalization method for differential expression analysis of RNA-seq data. Genome Biol 11:R25. http://dx.doi.org/10.1186/gb-2010-11-3-r25.
19. Schmittgen TD, Livak KJ. 2008. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3:1101–1108. http://dx.doi.org/10.1038/nprot.2008.73.
20. Antisfiero O, Muller A, Rame C, Chiioketo O, Chatterjee B, Raykova A, Planas R, Sospedra M, Shumilov A, Tsai MH, Delecluse HJ, Munz C. 2014. Adoptive transfer of EBV specific CD8+ T cell clones can transiently control EBV infection in humanized mice. PLoS Pathog 10:e1004333. http://dx.doi.org/10.1371/journal.ppat.1004333.